- Home
- / Alzamend Neuro
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Alzamend Neuro financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$1.6
2024-10-29
Market Capitalization
$7.2 M
2024-10-29
CreditSafe Score
?
Score changed on Jun 17, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|
| General and administrative expense | 3.6M | 7.1M | 7.4M | 3.5M | 3.1M |
| Operating expense total | 12.3M | 14.9M | 9.9M | 4.5M | |
| EBIT | (5.0M) | (12.3M) | (14.9M) | (9.9M) | (4.5M) |
| Interest expense | 1.7K | 7.7K | |||
| Pre tax profit | (5.0M) | (12.4M) | (14.9M) | (9.9M) | (4.5M) |
| Net Income | (5.0M) | (12.4M) | 14.9M | (9.9M) | (4.5M) |
| EPS | (0.1) | (14.7) | (11.3) |